http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115058504-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8eba54c6ec98cca9987495619a62a634 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6869 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57407 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6869 |
| filingDate | 2022-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d19e16b01d696249406d648c2f90224 |
| publicationDate | 2022-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-115058504-A |
| titleOfInvention | Bladder cancer TH17 CD4+ T cell subsets and their characteristic genes and applications |
| abstract | The invention discloses bladder cancer TH17CD4+ T cell subsets, characteristic genes and applications thereof, and relates to the technical field of biomedicine. A biomarker group for identifying, detecting or identifying TH17CD4+ T cells of the present invention, the biomarker group includes at least one of the genes IL17A, FURIN, CTSH, KLRB1, or a protein encoded by the gene or protein fragments. The characteristic genes IL17A, FURIN, CTSH and KLRB1 obtained by the screening of the present invention are lowly expressed in TH17CD4+ T cells of bladder cancer tissue, and can be used for the preparation of drugs for auxiliary tumor diagnosis, prognosis judgment and immunotherapy; the characteristic genes of the present invention are expressed in normal bladder The expression in the TH17CD4+T cells of the tissue is higher than that in the bladder cancer tissue, indicating that the characteristic gene of the present invention can promote the immune effect of TH17CD4+T, and can be used for the preparation of bladder cancer therapeutic drugs. |
| priorityDate | 2022-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 81.